Navigation Links
MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
Date:8/5/2013

MARIETTA, Ga., Aug. 5, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 33rd Annual Canaccord Genuity Growth Conference in Boston.  Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on August 14th at 11:30 a.m. EDT at the InterContinental Boston.  A webcast of this presentation will be available on the Company's website, www.mimedx.com

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 160,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
2. MiMedx Announces Record Second Quarter Results
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. MiMedx To Exceed High End Of Second Quarter Guidance
5. MiMedx to Ring NASDAQ Stock Market Opening Bell
6. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
7. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
8. MiMedx Announces Record First Quarter 2013 Results
9. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
10. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
11. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):